Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.

Zhao F, Evans K, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A, Siska PJ, Blobe GC, Hanks BA.

Cancer Immunol Res. 2018 Sep 12. doi: 10.1158/2326-6066.CIR-18-0086. [Epub ahead of print]

PMID:
30209062
2.

Endoglin interacts with VEGFR2 to promote angiogenesis.

Tian H, Huang JJ, Golzio C, Gao X, Hector-Greene M, Katsanis N, Blobe GC.

FASEB J. 2018 Jun;32(6):2934-2949. doi: 10.1096/fj.201700867RR. Epub 2018 Jan 11.

PMID:
29401587
3.

Endoglin Mediates Vascular Maturation by Promoting Vascular Smooth Muscle Cell Migration and Spreading.

Tian H, Ketova T, Hardy D, Xu X, Gao X, Zijlstra A, Blobe GC.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1115-1126. doi: 10.1161/ATVBAHA.116.308859. Epub 2017 Apr 27. Erratum in: Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):e67.

4.

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI.

Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619. doi: 10.1007/s00280-017-3256-2. Epub 2017 Feb 25.

PMID:
28238078
5.

Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.

Gaviglio AL, Knelson EH, Blobe GC.

FASEB J. 2017 May;31(5):1903-1915. doi: 10.1096/fj.201600828R. Epub 2017 Feb 7.

6.

Dichotomous roles of TGF-β in human cancer.

Huang JJ, Blobe GC.

Biochem Soc Trans. 2016 Oct 15;44(5):1441-1454. Review.

7.

TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.

Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC.

Carcinogenesis. 2016 Nov 1;37(11):1041-1051. doi: 10.1093/carcin/bgw093.

8.

An Automated High-throughput Array Microscope for Cancer Cell Mechanics.

Cribb JA, Osborne LD, Beicker K, Psioda M, Chen J, O'Brien ET, Taylor Ii RM, Vicci L, Hsiao JP, Shao C, Falvo M, Ibrahim JG, Wood KC, Blobe GC, Superfine R.

Sci Rep. 2016 Jun 6;6:27371. doi: 10.1038/srep27371.

9.

TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.

Tazat K, Hector-Greene M, Blobe GC, Henis YI.

Mol Biol Cell. 2015 Oct 1;26(19):3535-45. doi: 10.1091/mbc.E15-04-0203. Epub 2015 Aug 12.

10.

Regulation of TGF-β receptor hetero-oligomerization and signaling by endoglin.

Pomeraniec L, Hector-Greene M, Ehrlich M, Blobe GC, Henis YI.

Mol Biol Cell. 2015 Sep 1;26(17):3117-27. doi: 10.1091/mbc.E15-02-0069. Epub 2015 Jul 8.

11.

Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment.

Tian H, Liu J, Chen J, Gatza ML, Blobe GC.

Oncogene. 2015 Nov 5;34(45):5635-47. doi: 10.1038/onc.2015.13. Epub 2015 Mar 30.

12.

Erratum to: angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction.

Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, Chen L, Kokosis G, Ibrahim M, Selim A, Blobe GC, Levinson H.

J Mol Med (Berl). 2015 Mar;93(3):303. doi: 10.1007/s00109-015-1262-6. No abstract available.

PMID:
25676696
13.

Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction.

Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, Chen L, Kokosis G, Ibrahim M, Selim A, Blobe GC, Levinson H.

J Mol Med (Berl). 2015 Mar;93(3):289-302. doi: 10.1007/s00109-014-1211-9. Epub 2014 Oct 28. Erratum in: J Mol Med (Berl). 2015 Mar;93(3):303.

14.

TGF-β regulates LARG and GEF-H1 during EMT to affect stiffening response to force and cell invasion.

Osborne LD, Li GZ, How T, O'Brien ET, Blobe GC, Superfine R, Mythreye K.

Mol Biol Cell. 2014 Nov 5;25(22):3528-40. doi: 10.1091/mbc.E14-05-1015. Epub 2014 Aug 20.

15.

The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.

Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC.

Neoplasia. 2014 Jun;16(6):489-500. doi: 10.1016/j.neo.2014.05.008.

16.

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB.

Invest New Drugs. 2014 Oct;32(5):851-9. doi: 10.1007/s10637-014-0129-y. Epub 2014 Jul 5.

17.

Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.

Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC.

Mol Biol Cell. 2014 Aug 15;25(16):2320-32. doi: 10.1091/mbc.E13-09-0524. Epub 2014 Jun 25.

18.

Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, Blobe GC.

J Clin Invest. 2014 Jul;124(7):3016-31. doi: 10.1172/JCI74270. Epub 2014 Jun 17.

19.

Role of TGF-β receptor III localization in polarity and breast cancer progression.

Meyer AE, Gatza CE, How T, Starr M, Nixon AB, Blobe GC.

Mol Biol Cell. 2014 Aug 1;25(15):2291-304. doi: 10.1091/mbc.E14-03-0825. Epub 2014 May 28.

20.

Heparan sulfate signaling in cancer.

Knelson EH, Nee JC, Blobe GC.

Trends Biochem Sci. 2014 Jun;39(6):277-88. doi: 10.1016/j.tibs.2014.03.001. Epub 2014 Apr 19. Review.

21.

Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development.

Holtzhausen A, Golzio C, How T, Lee YH, Schiemann WP, Katsanis N, Blobe GC.

FASEB J. 2014 Mar;28(3):1248-67. doi: 10.1096/fj.13-239178. Epub 2013 Dec 5.

22.

Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC.

J Clin Invest. 2013 Nov;123(11):4786-98.

23.

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI.

Invest New Drugs. 2014 Apr;32(2):330-9. doi: 10.1007/s10637-013-0042-9. Epub 2013 Nov 1.

24.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S.

Clin Cancer Res. 2014 Jan 15;20(2):480-9. doi: 10.1158/1078-0432.CCR-13-1840. Epub 2013 Oct 30.

25.

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.

Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI.

Cancer Med. 2013 Jun;2(3):316-24. doi: 10.1002/cam4.65. Epub 2013 Mar 21.

26.

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC.

J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8.

27.

The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells.

Oh SY, Knelson EH, Blobe GC, Mythreye K.

Biochem J. 2013 Aug 15;454(1):79-89. doi: 10.1042/BJ20121701.

28.

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI.

Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13.

29.

Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells.

Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC.

EMBO J. 2012 Oct 3;31(19):3885-900. doi: 10.1038/emboj.2012.246. Epub 2012 Aug 31.

30.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI.

Cancer Chemother Pharmacol. 2012 Jul;70(1):95-102. doi: 10.1007/s00280-012-1889-8. Epub 2012 May 26.

31.

Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis.

Lee NY, Golzio C, Gatza CE, Sharma A, Katsanis N, Blobe GC.

Mol Biol Cell. 2012 Jul;23(13):2412-23. doi: 10.1091/mbc.E11-12-0993. Epub 2012 May 16.

32.

TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells.

Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC.

Oncogene. 2013 Mar 14;32(11):1416-27. doi: 10.1038/onc.2012.157. Epub 2012 May 7.

33.

Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC.

Townsend TA, Robinson JY, How T, DeLaughter DM, Blobe GC, Barnett JV.

Cell Signal. 2012 Jan;24(1):247-56. doi: 10.1016/j.cellsig.2011.09.006. Epub 2011 Sep 14.

34.

Molecular characterization of the tumor-suppressive function of nischarin in breast cancer.

Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, Pylayeva Y, Giancotti F, Blobe GC, Alahari SK.

J Natl Cancer Inst. 2011 Oct 19;103(20):1513-28. doi: 10.1093/jnci/djr350. Epub 2011 Sep 14.

35.

A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.

Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI.

Clin Colorectal Cancer. 2011 Sep;10(3):210-6. doi: 10.1016/j.clcc.2011.03.018. Epub 2011 Apr 24.

36.

Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.

Neoplasia. 2011 Aug;13(8):758-70.

37.

A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI.

Oncologist. 2011;16(8):1131-7. doi: 10.1634/theoncologist.2011-0078. Epub 2011 Jul 27.

38.

Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines.

Swaminathan V, Mythreye K, O'Brien ET, Berchuck A, Blobe GC, Superfine R.

Cancer Res. 2011 Aug 1;71(15):5075-80. doi: 10.1158/0008-5472.CAN-11-0247. Epub 2011 Jun 3.

39.

The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.

Lambert KE, Huang H, Mythreye K, Blobe GC.

Mol Biol Cell. 2011 May;22(9):1463-72. doi: 10.1091/mbc.E10-11-0877. Epub 2011 Mar 16.

40.

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI.

Anticancer Res. 2011 Jan;31(1):255-61.

41.

BMP-2 and TGFβ2 shared pathways regulate endocardial cell transformation.

Townsend TA, Robinson JY, Deig CR, Hill CR, Misfeldt A, Blobe GC, Barnett JV.

Cells Tissues Organs. 2011;194(1):1-12. doi: 10.1159/000322035. Epub 2011 Jan 7.

42.

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC.

Cancer Chemother Pharmacol. 2011 Feb;67(2):465-74. doi: 10.1007/s00280-010-1507-6. Epub 2010 Nov 16.

43.

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.

Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, Lagoo AS, Lugar PL, Mann KP, Flowers CR, Bernal-Mizrachi L, Naresh KN, Evens AM, Gordon LI, Luftig M, Friedman DR, Weinberg JB, Thompson MA, Gill JI, Liu Q, How T, Grubor V, Gao Y, Patel A, Wu H, Zhu J, Blobe GC, Lipsky PE, Chadburn A, Dave SS; Hematologic Malignancies Research Consortium.

Blood. 2010 Dec 2;116(23):e118-27. doi: 10.1182/blood-2010-05-285403. Epub 2010 Aug 23.

44.

A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.

Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, Fernando NH, Morse MA, Blobe GC, Hurwitz HI.

Anticancer Res. 2010 Apr;30(4):1251-6.

45.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

46.

Roles for the type III TGF-beta receptor in human cancer.

Gatza CE, Oh SY, Blobe GC.

Cell Signal. 2010 Aug;22(8):1163-74. doi: 10.1016/j.cellsig.2010.01.016. Epub 2010 Feb 12. Review.

47.

Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage.

Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Duménil D.

Blood. 2010 Apr 8;115(14):2784-95. doi: 10.1182/blood-2009-09-241752. Epub 2010 Feb 2.

48.

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

Dugan E, Truax R, Meadows KL, Blobe GC, Morse MA, Fernando NH, Gockerman JP, Petros WP, Hurwitz HI.

Anticancer Res. 2009 Dec;29(12):5149-53.

49.

ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration.

Ray BN, Lee NY, How T, Blobe GC.

Carcinogenesis. 2010 Mar;31(3):435-41. doi: 10.1093/carcin/bgp327. Epub 2009 Dec 30.

50.

The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Lee JD, Hempel N, Lee NY, Blobe GC.

Carcinogenesis. 2010 Feb;31(2):175-83. doi: 10.1093/carcin/bgp271. Epub 2009 Dec 2.

Supplemental Content

Loading ...
Support Center